Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Brady (NYSE:BRC), a global leader in product and ... testimonial on the effectiveness of its FreezerBondz™ specimen ... the BloodCenter of Wisconsin discusses the challenges she faces ... thousands of samples, and how the durability of Brady’s ... design our label materials with the harsh conditions of ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... 30, 2014 On October 26th ... Showcase in Chicago, leading applied stem cell research ... Wade McKenna presented talks on New Techniques for ... Applications For Stem Cells. , Dr. Riordan focused ... the properties of AlphaGEMS that include: wound healing; ...
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
Breaking Biology Technology:Brady Debuts New Lab Label Testimonial Video 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3
... two months ahead of schedule ... -, - Progress continues on LymphoStat-B, ABthrax and TRAIL receptor antibody ... programs - ... ROCKVILLE, Md., Nov. 1 Human Genome Sciences,Inc. (Nasdaq: HGSI ) today announced financial results ...
... CA -- Make way for the real nanopod and ... of researchers with the U.S. Department of Energys Lawrence ... California at Berkeley have created the first fully functional ... by several orders of magnitude the smallest radio ever ...
... - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; ... method,for 7ACA production has been successfully implemented ... achievement validates the Company,s research,and development efforts ... bring immediate benefits to production operations by,increasing ...
Cached Biology Technology:Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 9Make way for the real nanopod 2Make way for the real nanopod 3Make way for the real nanopod 4Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3
(Date:10/29/2014)... New research presented at the Society for Integrative ... showed for the first time that it is ... a readily available nutritional supplement, AHCC. ... A. Smith, Pharm.D., associate professor in the Department ... University of Texas Health Science Center at Houston ...
(Date:10/29/2014)... to make their food, but they also need protection from ... a group of molecules in plants that shields them from ... of the American Chemical Society , one team reports on ... Timothy Zwier and colleagues at Purdue University note that the ... serious damage to plant DNA and, as a result, hinder ...
(Date:10/29/2014)... a ceremony held in New York City on September ... the American Cancer Society Professor of Genome Sciences and ... 2008 Honorary Doctor of Philosophy of Tel Aviv University, ... Medical Science. , In addition to her honorary degree ... at the TAU School of Medicine, and for the ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... , No one is in a better position to monitor ... the people living there. But many scientists believe the ... is simply too great to bridge -- that native peoples ... But now, researchers led by Stanford ecologist Jose Fragoso have ...
... New research from the Universities of Portsmouth and Leicester has ... London as being part of a giant pterosaur ... and toothed animals. Dr David Martill from the University ... Leicester examined the fossil - which consisted of the tip ...
... eyes or legs, yet they are able to "see" and ... is controlled by a series of molecular-level signals between proteins ... The Plant Cell, University of Missouri scientists report ... plays in this molecular signaling pathway that regulates phototropism in ...
Cached Biology News:Can indigenous peoples be relied on to gather reliable environmental data? 2Can indigenous peoples be relied on to gather reliable environmental data? 3Tiny fossil fragment reveals giant-but-ugly-truth 2Tiny fossil fragment reveals giant-but-ugly-truth 3Protein plays role in helping plants see light 2
...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
Anti Autotaxin /ENPP2 , - (Rabbit)...
Biology Products: